id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-255746-ir73lpi8	Sirimaturos, Michael	Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients	2020-10-01		.txt	text/plain	4095	205	36	CONCLUSIONS: Based on clinical outcomes and mortality rates seen in previous reports of mechanically ventilated patients, tocilizumab, as part of the management strategy for severe coronavirus disease 2019, represents a promising option. While several reports on tocilizumab treatment in COVID-19 patients now exist, data pertaining specifically to tocilizumab use in a large cohort of critically ill patients on invasive ventilation is lacking (11, 12) . Thus, in this report, we describe the 21-day outcomes of mechanically ventilated patients with severe COVID-19 who received tocilizumab as part of their management strategy. Our report of tocilizumab in patients exclusively receiving invasive mechanical ventilation demonstrates a 21-day mortality of 21% and clinical improvement at day 21 in 58% of patients with severe disease. Preliminary data from the placebo-controlled trial of remdesivir, which subsequently led to its emergency use authorization by the FDA for treatment of severe COVID-19, do not demonstrate differences in recovery or mortality rates between the remdesivir and placebo groups among patients on invasive ventilation (21) .	./cache/cord-255746-ir73lpi8.txt	./txt/cord-255746-ir73lpi8.txt